Nanomark Therapeutics Wins 2010 NVC!

10 04 2010

Congratulations to Nanomark Therapeutics, the 2010 New Venture Championship Champions!

We’re one step closer to curing cancer as NanoMark Therapuetics from Louisville University won the 2010 New Venture Championship, a business plan competition held by the Charles H. Lundquist Center for Entrepreneurship of the University of Oregon, and was awarded $25,000.

NanoMark Therapeutics’ business plan introduces a product, AUra, that enhances the treatment of ovarian cancer by minimizing the negative side effects to healthy cells and limiting dosage requirements.

“It’s the top of the peak for us right now,” NanoMark Therapeutics Chief Medical Officer Dr. Gary Degen said. “The competition here was so strong and to walk out on top is beyond our wildest dreams.”

The second place team Mosaic Genetics LLC from the University of Oregon earned $10,000.

Winning the New Venture Championship means entry in the 2010 Moot Corp Competition, a business-plan contest held at The University of Texas at Austin. Because NanoMark Therapeutics already has earned a spot in the competition, Mosaic Genetics has earned an invitation to the competition.

Third place finisher, Green Valley Solar from the University of Arkansas, received $2,500, and two runner-up teams, Microfluidic of Purdue University and Bombyx Technologies of Cornell University each received $2,000.

NanoMark Therpeutics from Louisville University also won $1,000 for first place in the Tektronix Elevator Pitch competition and Cortical Concepts from Johns Hopkins University was awarded $1,000 for first place in the Tektronix Trade Show competition.

Green Valley Solar from the University of Arkansas was awarded $1,000 for having the best-written business plan.

In the Oregon Entrepreneurs Network Lightning Round, each of the following winning teams earned $1,250: A2K Technologies from University of Manitoba, Thermal Conservation from University of Illinois at Chicago, Mielixir from Sasin, SafeSnip from Tulane University, and R2EV from Boise State University won $1,250. All other teams competing were awarded $500 as runners-up.

For more information on the New Venture Championship, please go to


Nanomark Therapeutics – Finalist Presentation

10 04 2010

In 2010, it is predicted that cancer will become the most deadly disease worldwide. NanoMark Therapeutics decided to tackle the challenge of fighting cancer.

Dr. Sham Kakar, the founder of NanoMark Therapeutics, has created a groundbreaking new system of delivering drugs directly to the cancerous cells of the body while sparing healthy cells.

Louisville's five-person team graces the NVC stage

The system reduces the needed dosage by 200% and reduced total treatments from 24 to four. This reduction in dosage also decreases the risk of side effects. Each individual consumer dosage costs more than traditional cancer treatments, but with the reduced number of treatments the increase in cost to the patient is minimal.

The team is currently conducting their first round of animal testing and expects to begin clinical trials on humans in 2011. The team stressed that all research and development has been performed with grants from their school and organizations, and there has been no dilution of potential stock options for investors.

Mosaic Genetics LLC – Final Presentation

10 04 2010

One in three women and one in two men will develop cancer in their lifetime. Nearly everyone knows or will know someone with cancer. Mosaic Genetics LLC is revolutionizing cancer research, one mouse at a time. The trio from the University of Oregon is bringing to market a new drug discovery tool, which will allow scientists to unlock the secrets of cancer at the cellular level. Catering to scientists’ research, Mosaic Genetics LLC crafted the LumiMouse – a new model, single cell view that enables cancer to develop in a natural location.

The University of Oregon team flashes their "O" at the NVC

The LumiMouse provides a systematic view of what is going on inside the body, unlike the current mouse model, “xenograft.” Green illumination represents cancer and red illumination signifies healthy cells.  This enables scientists to see what is happening in every individual cancer cell and every individual healthy cell. The LumiMouse also develops cancer for every test.

Providing detailed examples about their competitors, Mosaic Genetics LLC has developed their marketing strategy around academic validation with targeted researchers and commercial customers. They expect an 18-24 month product development stage and currently have a patent, filed in August 2009, covering targeted cancer growth and the dual color illumination.

With $100,000 current funds from family, friends and founders, Mosaic Genetics LLC predicts two phases of outside investment totaling $4 million. Within five years, the LumiMouse will come in five models for cancer research: breast, brain, prostate, colon and lung.

Teammates Elizabeth Holsapple, Nick Boehm and Yonatan Schultz equally answered the finalist judges’ Q&A session promptly and efficiently and stood proud representing their new cancer research tool in the form of a mouse. Mosaic Genetics LLC predicts three hurdles, including licensing the red and green fluorescents, use of mice because LumiMouse cannot breed, and personnel.

Green Valley Solar Presents in the Final Round

10 04 2010

Green Valley Solar from the University of Arkansas plans to better the world by improving the solar generated electricity. Addressing high manufacturing in the solar market come from wasted materials, the team introduced a solution to this issue with promising “solar has never been so green.”

Green Valley Solar, represented by senior scientist, Seth Shumate, and vice president of communications, Stephan Ritterbush, has worked with their team to develop a large-grain polysilicon cell solution generating grains 90 times larger, thus separating boundaries and reducing silicon costs. There are currently two types of crystalline silicon used in the industry. Green Valley Solar is striving to by-pass the waste and inefficiencies that each of these production processes can cause.

The two representatives from the University of Arkansas grace the stage

Materials used by competing products have proven to be highly toxic. Shumate and Ritterbush spoke to the idea that the European Union is in the process of working against such products for this exact reason. Not only has Green Valley Solar solidified an experienced management team to confront this problem, but the team also capitalizes on the low toxicity of their cell structure.

Green Valley Solar’s technological solution has been protected by five patents, of which two are related to grain size and three are related to medal induced crystallization. With these patents, Shumate and Ritterbush ensured the judging panel that their technology was secure and prepared to move forward.

And, moving forward they are.

Green Valley Solar has already earned the compliance of the Department of Energy, established a relationship with Sanyo to produce samples and scheduled a meeting with Sharp. In the coming months, Green Valley Solar plans to engage in heat sample testing and can take their experiences at the NVC in the continuation of their venture.

Microfluidic Innovations LLC – Finalist Presentation

10 04 2010

Worldwide pandemics such as H1N1 cause death and destruction. However, these are preventable. Microfluidics Innovations LLC is marketing a better opportunity for scientists to find a cure.

The venture, traveling from Purdue University, focuses on minute amounts of liquid being processed in order to do research in the fields of biochemistry, genomics, biotechnology and DNA analysis. Much of this research is accomplished by using lab-on-a-chip technology, which utilizes small glass chips with grooves to channel and alter liquids.

Microfluidic Innovations LLC has created a revolutionary new form of lab-on-a-chip that is infinitely programmable to match the desires of research labs and pharmaceutical companies. A lab currently must go through the time-intensive process of designing, fabricating, and testing chips, and often would have to return to each step multiple times in order to get what they needed.

With the new technology that team members Leonard Kim and Samir Sahoo propose, labs will only have

Microfluidic Innovations LLC poses for the camera

to create an idea, write a simple program or click a few buttons, and produce a working chip that can be used directly in experiments. Instead of a production timeline of 3-6 months, the whole process can be completed in 3-6 hours.

The team already has an international patent on their technology, with two more patents pending, and an exclusive license with Purdue University to use the technology.

Microfluidic Innovations, LLC hopes to tap into a $56 billion dollar market that is expected to grow annually by 13%. They plan on offering their new chips to researchers who are required to mention the product, and parlay that free advertising into sales agreements with both academic organizations and companies that use the chips.

Bombyx Technologies – Final Round

10 04 2010

Over five million eye injuries in America each year, many of which result with a slow and low recovery rate that often takes months and can even result in blindness. Bombyx Technologies, which includes team members Benjamin Rollins and Brian Lawrence (a co-inventor), has created the first regenerative bandage for the eye that absorbs, dissolves and rapidly heals wounds within only a few weeks.

Cornell University presented with class and poise in the finals

Rollins and Lawrence were well composed while presenting their regenerative eyesight bandage. The team currently has more than $1 million in funds distributed from Cornell University. Bombyx Technologies’ bandage not only protects, it also replaces and regenerates over a two-week span. Similar to a contact lens, their product is comprised of a special substance that adheres to the eye to repair soft tissue; then it rapidly dissolves. It’s that simple! Bombyx absorbs to your eye while healing, and dissolves to shield and protect.

Lawrence gave an example of a friend of his who had recently fell asleep with her contacts in – a common occurrence among contact lens wearers. The next morning her contacts had dried up so extensively that she tore off part of her cornea trying to remove it. Constructive surgery is expensive, painful and requires a long recovery. Lawrence indicated that it’s likely that if his friend had been able to use Bombyx Technologies’ bandage, she would have had full recovery within two weeks.

With the “potential to revolutionize,” the bandage has a remarkable one-year shelf life.

Bombyx Technologies has a market strategy including strong relationships with key opinion leaders, PRK laser surgeons, ophthalmologists and ER physicians. Although they already have a prototype, Rollins and Lawrence need to begin clinical trials, which will start in the Dominican Republic. By year five of their product launch, they project the bandage will be in 900 of 1,200 desired locations

Schedule of Finalists

10 04 2010

Today’s finalists are now underway.

Here is the schedule of presenters:

9:00 a.m. Bombyx Technologies (Cornell University)
10:00 a.m. Microfluidic Innovations LLC (Purdue University)
11:00 a.m. Green Valley Solar (University of Arkansas)
12:30 p.m. Mosaic Genetics (University of Oregon)
1:30 p.m. NanoMark Therapeutics (University of Louisville)

Stay tuned for updates on the day. For more information, visit our Twitter page or